Oxford Biomedica
Block Listing Application
Oxford, UK -
25 July 2024: Oxford Biomedica plc
(LSE:OXB) ("Oxford Biomedica" or "the Company"), a
quality and innovation-led cell and gene therapy CDMO, today
announces that application has been made to the
Financial Conduct Authority and the London Stock Exchange for
admission to (i) the Premium segment of the Official List and (ii)
to trading on the London Stock Exchange for a block listing of
100,000 ordinary shares of 50 pence each (the "Ordinary
Shares").
The Ordinary Shares are being reserved under a
block listing and will be issued from time to time pursuant to the
following schemes:
· OXB Long Term
Incentive Plan (LTIP) (100,000 Ordinary Shares);
It is expected that admission to the Official
List and the London Stock Exchange of the New Ordinary Shares will
become effective on 26th July 2024. The New Ordinary
Shares will rank pari passu in all respects with the Group's
existing ordinary shares in issue.
-Ends-
|
For further
information, please contact:
|
|
|
Oxford
Biomedica plc:
Natalie Walter, Company Secretary
|
Tel: +44 (0)1865 783 000
|
ABOUT OXFORD
BIOMEDICA
Oxford Biomedica (LSE: OXB) is a quality and
innovation-led contract development and manufacturing organisation
(CDMO) in cell and gene therapy with a mission to enable its
clients to deliver life changing therapies to patients around the
world.
One of the original pioneers in cell and gene
therapy, OXB has more than 25 years of experience in viral vectors;
the driving force behind the majority of cell and gene therapies.
OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV), adenovirus, and other viral vector
types. Oxford Biomedica's world-class capabilities span from
early-stage development to commercialisation. These capabilities
are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is
headquartered in Oxford, UK. It has
bioprocessing and manufacturing facilities across Oxfordshire, UK,
Lyon and Strasbourg, France, and near Boston, MA, US. Learn more
at www.oxb.com, and follow us on
LinkedIn
and YouTube.